Moxifloxacin
Based on 23 publication(s) in Google Scholar
Moxifloxacin is an orally active 8-methoxyquinolone antimicrobial for use in the treatment of acute bacterial sinusitis, acute bacterial exacerbations of chronic bronchitis, and community-acquired pneumonia.
For research use only. We do not sell to patients.
- Purity: 99.75%
- CAS No.: 151096-09-2
- Formula: C21H24FN3O4
- Molecular Weight:401.43
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Moxifloxacin
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Nat Microbiol. 2023 Mar;8(3):410-423. [Abstract]
- Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
- Cell Mol Life Sci. 2022 Jul 22;79(8):441. [Abstract]
- J Clin Microbiol. 2025 Aug 20:e0084125. [Abstract]
- Int J Pharm. 2026 Jan 5:687:126356. [Abstract]
- Molecules. 2025 Mar 9;30(6):1224. [Abstract]
- Antibiotics (Basel). 2022 Feb 1;11(2):192. [Abstract]
- Antimicrob Agents Chemother. 2025 Sep 11:e0079525. [Abstract]
- Antimicrob Agents Chemother. 2025 May 23:e0024925. [Abstract]
- mLife. 2025 Apr 15;4(2):155-168. [Abstract]
- Antimicrob Agents Chemother. 2024 Oct 29:e0094524. [Abstract]
- Antimicrob Agents Chemother. 2024 Oct 29:e0105124. [Abstract]
- FASEB J. 2026 Feb 28;40(4):e71586. [Abstract]
- Microbiol Spectr. 2025 May 19:e0307424. [Abstract]
- ACS Chem Biol. 2022 Jan 21;17(1):39-53. [Abstract]
- Water. 2025 Jun 6.
- Infect Drug Resist. 2021 Sep 14;14:3729-3736. [Abstract]
- SSRN. 2025 Oct 14.
- SSRN. 2025 Oct 20.
- Authorea. 2025 Sep 17.
- bioRxiv. 2024 Nov 06.
- Universität zu Lübeck. 2022.
All Antibiotic Isoforms
More
Biological Activity
|
Quinolone |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
173 μM
Compound: moxifloxacin
|
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits
|
[PMID: 23812503] |
| HEK293 | IC50 |
168.9 μM
Compound: Moxifloxacin
|
Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit
Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit
|
[PMID: 22761000] |
| HeLa | IC50 |
110 μg/mL
Compound: Moxifloxacin
|
Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs
Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs
|
[PMID: 17088489] |
| HeLa | IC50 |
320 μg/mL
Compound: Moxifloxacin
|
Antiproliferative effect against HeLa cells after 48 hrs
Antiproliferative effect against HeLa cells after 48 hrs
|
[PMID: 17088489] |
| HeLa | IC50 |
320 μM
Compound: Moxifloxacin
|
Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA
Inhibition of human HeLa cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA
|
[PMID: 19595598] |
| HEp-2 | CC50 |
>100 μM
Compound: MXF
|
Cytotoxicity against human Hep2 cell line after 72 hrs
Cytotoxicity against human Hep2 cell line after 72 hrs
|
[PMID: 17228862] |
| HEp-2 | CC50 |
>100 μM
Compound: MXF
|
Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay
Cytotoxicity against human Hep2 cells after 72 hrs by alamar blue assay
|
[PMID: 21425851] |
| HEp-2 | CC50 |
>100 μM
Compound: MXF
|
Cytotoxicity against human Hep2 cell line after 72 hrs
Cytotoxicity against human Hep2 cell line after 72 hrs
|
[PMID: 21443219] |
| HEp-2 | CC50 |
>100 μM
Compound: moxifloxacin
|
Cytotoxicity against Hep2 cell line
Cytotoxicity against Hep2 cell line
|
[PMID: 16337789] |
| HEp-2 | CC50 |
>100 μM
Compound: moxifloxacin
|
Cytotoxicity against human Hep2 laryngeal carcinoma cell line
Cytotoxicity against human Hep2 laryngeal carcinoma cell line
|
[PMID: 16337791] |
| Hepatocyte | CC50 |
>100 μM
Compound: MXF
|
Cytotoxicity against rat hepatocytes after 48 hrs
Cytotoxicity against rat hepatocytes after 48 hrs
|
[PMID: 17228862] |
| HepG2 | CC50 |
>100 μM
Compound: MXF
|
Cytotoxicity against human HepG2 cells after 72 hrs
Cytotoxicity against human HepG2 cells after 72 hrs
|
[PMID: 17228862] |
| HepG2 | EC50 |
>100 μM
Compound: 2
|
Cytotoxicity against human HepG2 cells after 72 hrs by CellTiter Glo assay
Cytotoxicity against human HepG2 cells after 72 hrs by CellTiter Glo assay
|
[PMID: 33929852] |
| HepG2 | IC50 |
>50 μM
Compound: Moxifloxacin
|
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human HepG2 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 35500229] |
| J774.A1 | IC50 |
14.56 μg/mL
Compound: MOX
|
Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-dye based analysis
Cytotoxicity against mouse J774.A1 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-dye based analysis
|
[PMID: 35486992] |
| K562 | EC50 |
>100 μM
Compound: 2
|
Cytotoxicity against human K562 cells after 72 hrs by CellTiter Glo assay
Cytotoxicity against human K562 cells after 72 hrs by CellTiter Glo assay
|
[PMID: 33929852] |
| L6 | IC50 |
5.7783 μM
Compound: Moxifloxacin
|
Cytotoxicity against rat L6 cells assessed as inhibition of cell viability incubated for 24 hrs by MTT assay
Cytotoxicity against rat L6 cells assessed as inhibition of cell viability incubated for 24 hrs by MTT assay
|
[PMID: 32623216] |
| MDCK | CC50 |
161 μM
Compound: MXFX
|
Cytotoxicity against MDCK cells after 48 hrs by CPE assay
Cytotoxicity against MDCK cells after 48 hrs by CPE assay
|
[PMID: 21481984] |
| MG-63 | IC50 |
170 μg/mL
Compound: Moxifloxacin
|
Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs
Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs
|
[PMID: 17088489] |
| MG-63 | IC50 |
230 μg/mL
Compound: Moxifloxacin
|
Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs
Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs
|
[PMID: 17088489] |
| MG-63 | IC50 |
230 μM
Compound: Moxifloxacin
|
Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA
Inhibition of human MG63 cell proliferation assessed as bromodeoxyuridine incorporation during DNA synthesis after 48 hrs by ELISA
|
[PMID: 19595598] |
| MRC5 | IC50 |
>100 μg/mL
Compound: MOX
|
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-dye based analysis
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-dye based analysis
|
[PMID: 35486992] |
| MRC5 | IC50 |
10.9 μM
Compound: Moxifloxacin (MFLX)
|
In vitro inhibitory activity on MRC5 fibroblast tissue cultures inoculated with virulent RH strain of Toxoplasma gondii
In vitro inhibitory activity on MRC5 fibroblast tissue cultures inoculated with virulent RH strain of Toxoplasma gondii
|
[PMID: 15125930] |
| NIH3T3 | IC50 |
379.82 μg/mL
Compound: Moxifloxacin
|
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay
|
[PMID: 28174104] |
| Osteoblast | IC50 |
>400 μg/mL
Compound: Moxifloxacin
|
Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs
Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs
|
[PMID: 17088489] |
| Osteoblast | IC50 |
160 μg/mL
Compound: Moxifloxacin
|
Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs
Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs
|
[PMID: 17088489] |
| THP-1 | EC50 |
5.07 mg/L
Compound: Moxifloxacin
|
Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 10% FBS
Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 10% FBS
|
[PMID: 20385862] |
| THP-1 | EC50 |
5.21 mg/L
Compound: Moxifloxacin
|
Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 20% FBS
Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 20% FBS
|
[PMID: 20385862] |
| THP-1 | EC50 |
8.09 mg/L
Compound: Moxifloxacin
|
Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 2% FBS
Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 2% FBS
|
[PMID: 20385862] |
| Vero | CC50 |
128 μg/mL
Compound: Moxifloxacin
|
Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells incubated for 72 hrs by MTT assay
|
[PMID: 31352245] |
| Vero | CC50 |
128 μg/mL
Compound: MXF
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 29227930] |
The in vitro activities of Moxifloxacin and Amoxicillin are compared by time-kill curve and inhibition of intracellular growth experiments by using a model of bone marrow-derived mouse macrophages infected by L. monocytogenes EGDe. Moxifloxacin acts much more rapidly, beginning to exert its effects in the first 3 h and achieving complete broth sterilization within 24 h of incubation. Moxifloxacin appears to have a protective effect against macrophage lysis, as many cells are still viable after 24 h of incubation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:144 white male Wistar rats (18-22 weeks; 300-400 g) infected Stenotrophomonas maltophilia[4]
-
Dosage:12 mg/kg
-
Administration:Intravenous injection; once per day, twice per day, three times per day; for 7 days
-
Result:Showed considerably less bacterial overgrowth in the spleens and lungs and without being toxic.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 151096-09-2
-
Appearance Solid
-
Molecular Weight 401.43
-
Formula C21H24FN3O4
-
Color White to yellow
-
SMILES
O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N(C4)C[C@]5([H])[C@@]4([H])CCCN5)=C3OC)C1=O)O
-
Synonyms
BAY 12-8039 free base
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (23)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Nat Microbiol
Characterization of antibiotic resistomes by reprogrammed bacteriophage-enabled functional metagenomics in clinical strains. [Abstract]2023 Mar;8(3):410-423. PMID: 36759752 -
Nat Commun
Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]2022 Mar 2;13(1):1116. PMID: 35236849 -
Cell Mol Life Sci
2022 Jul 22;79(8):441. PMID: 35864358 -
J Clin Microbiol
Luciferase reporter mycobacteriophage (TM4:: GeNL) enables rapid assessment of drug susceptibilities and inducible macrolide resistance in Mycobacterium abscessus complex. [Abstract]2025 Aug 20:e0084125. PMID: 40833127 -
Int J Pharm
Modelling lung permeability of pharmaceuticals: The effectiveness of biomimetic open tubular capillary electrochromatography and immobilised artificial membrane chromatography coupled with mass spectrometry. [Abstract]2026 Jan 5:687:126356. PMID: 41205685 -
Molecules
Seeking Correlation Among Porin Permeabilities and Minimum Inhibitory Concentrations Through Machine Learning: A Promising Route to the Essential Molecular Descriptors. [Abstract]2025 Mar 9;30(6):1224. PMID: 40142001 -
Antibiotics (Basel)
Antibacterial Activity of the Novel Drug Gepotidacin against Stenotrophomonas maltophilia-An In Vitro and In Vivo Study. [Abstract]2022 Feb 1;11(2):192. PMID: 35203795 -
Antimicrob Agents Chemother
Incorporation of macrophage immune stresses into an intracellular assay of drug tolerance in Mycobacterium tuberculosis. [Abstract]2025 Sep 11:e0079525. PMID: 40934365 -
Antimicrob Agents Chemother
An enoyl-ACP reductase inhibitor, NITD-916, expresses anti- Mycobacterium abscessus activity. [Abstract]2025 May 23:e0024925. PMID: 40407337 -
mLife
Identification of a phenyl ester covalent inhibitor of caseinolytic protease and analysis of the ClpP1P2 inhibition in mycobacteria. [Abstract]2025 Apr 15;4(2):155-168. PMID: 40313980 -
Antimicrob Agents Chemother
2024 Oct 29:e0094524. PMID: 39470202 -
Antimicrob Agents Chemother
Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA of Mycobacterium abscessus. [Abstract]2024 Oct 29:e0105124. PMID: 39470195 -
FASEB J
Moxifloxacin Inhibits Neutrophil Responses to Immune Complexes and Ameliorates Skin Inflammation in a Model of Pemphigoid Diseases. [Abstract]2026 Feb 28;40(4):e71586. PMID: 41676900 -
Microbiol Spectr
Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan. [Abstract]2025 May 19:e0307424. PMID: 40387379 -
ACS Chem Biol
Investigate Natural Product Indolmycin and the Synthetically Improved Analogue Toward Antimycobacterial Agents. [Abstract]2022 Jan 21;17(1):39-53. PMID: 34908399 -
-
Infect Drug Resist
In vitro Synergism of Six Antituberculosis Agents Against Drug-Resistant Mycobacterium tuberculosis Isolated from Retreatment Tuberculosis Patients. [Abstract]2021 Sep 14;14:3729-3736. PMID: 34548797 -
-
-
-
-
Solvent & Solubility
DMSO : 31.25 mg/mL (77.85 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (6.23 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.23 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (597 KB)
- English - EN (597 KB)
- Français - FR (597 KB)
- Deutsch - DE (597 KB)
- Norwegian - NO (597 KB)
- Español - ES (597 KB)
- Swedish - SV (597 KB)
- Italian - IT (597 KB)
- Korean - KR (597 KB)
- Portuguese - PT (597 KB)
-
Handling Instructions (2659 KB)
References
[1]. Culley, C.M., et al., Moxifloxacin: clinical efficacy and safety. Am J Health Syst Pharm, 2001. 58(5): p. 379-88. [Content Brief]
[2]. Grayo S, et al. Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes. Antimicrob Agents Chemother. 2008 May;52(5):1697-702. [Content Brief]
[3]. Balfour JA, et al. Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs. 2000 Jan;59(1):115-39. [Content Brief]
[4]. Ioannidis O, et al. Effect of moxifloxacin on survival, lipid peroxidation and inflammation in immunosuppressed rats with soft tissue infection caused by Stenotrophomonas maltophilia. Microbiol Immunol. 2014 Feb;58(2):96-102. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.4911 mL | 12.4555 mL | 24.9109 mL | 62.2774 mL |
| 5 mM | 0.4982 mL | 2.4911 mL | 4.9822 mL | 12.4555 mL | |
| 10 mM | 0.2491 mL | 1.2455 mL | 2.4911 mL | 6.2277 mL | |
| 15 mM | 0.1661 mL | 0.8304 mL | 1.6607 mL | 4.1518 mL | |
| 20 mM | 0.1246 mL | 0.6228 mL | 1.2455 mL | 3.1139 mL | |
| 25 mM | 0.0996 mL | 0.4982 mL | 0.9964 mL | 2.4911 mL | |
| 30 mM | 0.0830 mL | 0.4152 mL | 0.8304 mL | 2.0759 mL | |
| 40 mM | 0.0623 mL | 0.3114 mL | 0.6228 mL | 1.5569 mL | |
| 50 mM | 0.0498 mL | 0.2491 mL | 0.4982 mL | 1.2455 mL | |
| 60 mM | 0.0415 mL | 0.2076 mL | 0.4152 mL | 1.0380 mL |
Powered by Bioz